Aparna Kalyan is an Oncology physician affiliated with Northwestern University. OpenAlex indexes 83 publications with 2,991 citations (h-index 29); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
645 N Michigan Ave
Suite 1006
Chicago, IL 606112826
Telephone
312-926-2000Registry record last updated 8 Aug 2014.
Clinical trials
- Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
Sponsor: Northwestern University
- Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer
Sponsor: Northwestern University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year202517 payments$14,989openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year202510 payments$11,309openpaymentsdata.cms.gov ↗
- Corcept TherapeuticsProgram year20257 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
53.5%CD38-directed Cytolytic Antibody25.3%Daratumumab100%Part B, office-administered≥50 patientsPD-1 inhibitor10.1%Pembrolizumab100%Part B, office-administered≥16 patients+ 4 more classes in this area
Blood & clotting
12%Iron, parenteral preparations12%Ferric carboxymaltose100%Part B, office-administered≥11 patientsFactor Xa inhibitor0%Eliquis54%Xarelto46%Part D<11 patientsDermatology
11.7%Corticosteroid11.7%Methylprednisolone sodium succinate100%Part B, office-administered≥48 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Leveraging radiomics and AI for precision diagnosis and prognostication of liver malignancies
Frontiers in Oncology
2024 - Radiation Segmentectomy and Modified Radiation Lobectomy for Unresectable Early-Stage Intrahepatic Cholangiocarcinoma
Journal of Vascular and Interventional Radiology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Clyde Yancy, MD
Northwestern University
Philip Greenland, MD
Northwestern University
Peter Kahrilas, MD
Northwestern University
Philip Gorelick, MD
Northwestern University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”